

Bloomberg	AMS SW
Reuters	AMS.S
12-month High / Low (CHF)	39.3 / 23.0
Market Cap (CHFm)	2,217
Ev (BG Estimates) (CHFm)	2,401
Avg. 6m daily volume (000)	466.2
3y EPS CAGR	9.4%

Yesterday, ams reported Q3 revenue of EUR146.7m, with an adj. operating result of EUR28m (adj. op. margin of 19.1%), yielding EPS of EUR0.37, i.e. well above Street's expectations (at EUR0.29). However, the group sees a muted year-end, as such Q4 2016 adj. EBIT revenue and guidance came out well below consensus. But the most important part of the press release is the announcement of the acquisition of Heptagon in a deal worth USD570m (+ possible earn-out consideration of USD285m) that we believe will not be accretive before 2018e. A conference call is to be held today at 9:00am (CET). In the meantime, we set our FV Under Review vs. CHF29.

	1 M	3 M	6 M	31/12/15
Absolute perf.	-10.9%	8.4%	-1.3%	-10.0%
Semiconductors	0.3%	6.2%	30.8%	24.2%
DJ Stoxx 600	-0.3%	1.2%	-1.2%	-5.9%


## ANALYSIS

YEnd Dec. (EURm)	2015	2016e	2017e	2018e
Sales	623.1	582.5	688.2	826.7
% change		-6.5%	18.1%	20.1%
EBITDA	195	146	213	276
EBIT	147.3	86.9	154.8	219.1
% change		-41.0%	78.2%	41.5%
Net income	148.7	83.6	142.3	200.1
% change		-43.8%	70.2%	40.6%

	2015	2016e	2017e	2018e
Operating margin	23.6	14.9	22.5	26.5
Net margin	23.9	14.4	20.7	24.2
ROE	21.8	12.2	17.1	19.4
ROCE	17.0	9.4	16.1	21.5
Gearing	19.3	26.8	1.8	-13.3

(EUR)	2015	2016e	2017e	2018e
EPS	2.08	1.14	1.94	2.73
% change	-	-45.2%	70.2%	40.6%
P/E	14.5x	26.5x	15.6x	11.1x
FCF yield (%)	3.3%	NM	7.0%	8.3%
Dividends (EUR)	0.31	0.47	0.26	0.44
Div yield (%)	1.0%	1.6%	0.9%	1.5%
EV/Sales	3.8x	4.1x	3.2x	2.5x
EV/EBITDA	12.0x	16.4x	10.5x	7.5x
EV/EBIT	15.9x	27.6x	14.4x	9.5x

- ams reported Q3 EPS well above the Street's expectations.** For Q3, ams reported revenues of EUR146.7m, up 10.8% seq. (-4.1% yoy) compared with group's guidance for a revenue of about EUR149.5m (at mid-range, i.e. flat seq.), and consensus expectations for revenue of EUR149.7m or up 13.1% sequentially. Gross margin came in at 55.0%, about 100bps below company's guidance (56.0%) and broadly in line with the street's forecast of GM at 54.6% (BG ests. 55.5%). As a result, EBIT was well above expectations at EUR28m (cons. USD22m/BG ests. EUR27m) (IFRS EBIT of EUR49.7m or a 34% op. margin) and EPS came in at EUR0.37, i.e. well above the consensus (cons. EUR0.29/BG ests. EUR0.32). Finally, backlog on Q3 was EUR132.2m down from EUR146.6m at the end of Q2 2016.
- A strong Q3 thanks to higher volume demand.** The ams' consumer and communications business played a significant role in the good performance of Q3 with high volume thanks to new smartphone launches and a more attractive market environment driving strong momentum for products such as ambient light sensors. On the other hand, ams' industrial, medical and automotive performed in line with expectations.
- Company sees a muted year-end, as such Q4 2016 revenue and operating result guidance came out well below expectations.** For Q4, the group sees a muted environment due to a negative impact at a specific customer (i.e. Samsung Galaxy Note7), but especially a production yield issue in an industrial product line which is not expected to be resolved before early 2017. As such, ams expects Q4 2016 sales to decrease sequentially by 11.0% to about EUR130m (at the mid-range of EUR127m to EUR134m), well below (c. 17%) the consensus forecasts for revenue of EUR157.2m (BG ests. EUR160.8m). Margins should also be impacted by the production yield issue. As such, the adjusted operating margin for Q4 2016 is forecast to be around 12% at mid-range (+/-100bp), yielding Adj. EBIT of EUR16m, well below (about 45%) consensus forecasting Adj. EBIT of EUR28m.
- ams also announces the acquisition of Heptagon for about EUR520m (USD570m) upfront and earn-out consideration of EUR260m (USD285m) maximum.** Heptagon is focusing on optical packaging of components designed for consumer applications. ams sees an opportunity to expand its know-how in optical design and manufacturing while accelerating ams' mid-term growth in optical sensing. We understand that Heptagon won an important design-in lately in the smartphone space (possibly Apple or Samsung). As such, based on the current pipeline and customers engagements, ams forecasts Heptagon revenue to increase significantly (2015/19e CAGR > 30%). The current revenue run rate of Heptagon is about EUR80m (USD90m), but is said to be below the break-even at EBIT level. We understand that ams targets revenue of about EUR180m as of 2019e with EBIT margin of about 30% or 2019e EBIT slightly below EUR54m. The acquisition is said to be financed through 1/ a cash consideration of USD64m (c. EUR59m; note that the group had a net debt position of EUR280m at the end of Q2 2016), 2/ a capital increase of 15% of outstanding shares, and 3/ shares from currently held treasury shares for a deal worth USD570m or EUR520m pointing to deal value to TTM (trailing twelve months) sales ratio of 6.3x. In addition to this upfront transaction, ams might pay an earn-out of maximum EUR260m or USD285m depending on Heptagon performance over FY17. The transaction is expected to close within the next three months.
- An acquisition likely not accretive before 2018e.** Given the details shared by the group, we estimate that the acquisition has high chance to be accretive from 2018e only. Currently, Heptagon is below break-even at operating result level. Including the impact of the acquisition (mainly the capital increase), we estimate at first take that Heptagon business would require an operating margin of 12% in 2017e to be accretive (implying a 30% revenue growth in 2017e based



on current 12m run rate). Given the cautious wording of ams regarding the ramp up of Heptagon revenue, we estimate that 2018e will be the year when this acquisition will finally be accretive (requires an operating margin of 13% minimum to be accretive, based on similar assumptions).

#### VALUATION

- Before the conference call to be held today at 9:00am, we set our FV Under Review (vs. EUR29).
- Based on our estimates, ams' shares are trading on 2017e P/E and PEG ratios of 15.3x and 1.6x respectively.

#### NEXT CATALYSTS

- 25 October 2016: Q3 results Conference call (9 am CET: +44 20 3059 5862)
- Early February 2017: FY16 and Q4 results

#### Reported Q3 2016 vs. estimates

[EURm]	BG ests. 3Q16e	Consensus 3Q16e	3Q16 Actual	Actual vs. Cons.
Net revenue	152.6	149.7	146.7	-2.0%
% change (seq)	15.3%	13.1%	10.8%	-227bp
% change (yoy)	-0.3%	-2.2%	-4.1%	-196bp
Adj. Gross Margin	55.5%	54.6%	55.0%	40bp
Adj. EBIT	26.9	21.7	28.0	29.0%
% of revenue	17.6%	14.5%	19.1%	459bp
EPS (in EUR)	0.32	0.29	0.37	27.6%

Sources: ams; Thomson Reuters I.B.E.S; Bryan, Garnier & Co ests.

#### Guidance Q4 2016 vs. estimates

[EURm]	BG ests. 4Q16e	Consensus 4Q16e	4Q16 Guidance	Guid. vs. Cons.
Net revenue	161.7	157.2	130.5	-17.0%
% change	5.9%	5.0%	-11.0%	-1604bp
Gross Margin	56.5%	54.7%	54.7%	0bp
Adj. EBIT	32.4	28.4	15.7	-44.9%
% of revenue	20.1%	18.1%	12.0%	-607bp
EPS (in EUR)	0.39	0.36		

Sources: ams; Thomson Reuters I.B.E.S; Bryan, Garnier & Co ests.

[Click here to download document](#)



**Analyst :**  
Dorian Terral  
33(0) 1.56.68.75.92  
dterral@bryangarnier.com

**Sector Team :**  
Richard-Maxime Beaudoux  
Thomas Coudry  
Gregory Ramirez

# Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

## Stock rating

BUY	Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
NEUTRAL	Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
SELL	Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

## Distribution of stock ratings

BUY ratings 57.3%

NEUTRAL ratings 31.2%

SELL ratings 11.5%

# Research Disclosure Legend

1	Bryan Garnier shareholding in Issuer	Bryan Garnier & Co Limited or another company in its group (together, the "Bryan Garnier Group") has a shareholding that, individually or combined, exceeds 5% of the paid up and issued share capital of a company that is the subject of this Report (the "Issuer").	No
2	Issuer shareholding in Bryan Garnier	The Issuer has a shareholding that exceeds 5% of the paid up and issued share capital of one or more members of the Bryan Garnier Group.	No
3	Financial interest	A member of the Bryan Garnier Group holds one or more financial interests in relation to the Issuer which are significant in relation to this report	No
4	Market maker or liquidity provider	A member of the Bryan Garnier Group is a market maker or liquidity provider in the securities of the Issuer or in any related derivatives.	No
5	Lead/co-lead manager	In the past twelve months, a member of the Bryan Garnier Group has been lead manager or co-lead manager of one or more publicly disclosed offers of securities of the Issuer or in any related derivatives.	No
6	Investment banking agreement	A member of the Bryan Garnier Group is or has in the past twelve months been party to an agreement with the Issuer relating to the provision of investment banking services, or has in that period received payment or been promised payment in respect of such services.	No
7	Research agreement	A member of the Bryan Garnier Group is party to an agreement with the Issuer relating to the production of this Report.	No
8	Analyst receipt or purchase of shares in Issuer	The investment analyst or another person involved in the preparation of this Report has received or purchased shares of the Issuer prior to a public offering of those shares.	No
9	Remuneration of analyst	The remuneration of the investment analyst or other persons involved in the preparation of this Report is tied to investment banking transactions performed by the Bryan Garnier Group.	No
10	Corporate finance client	In the past twelve months a member of the Bryan Garnier Group has been remunerated for providing corporate finance services to the issuer or may expect to receive or intend to seek remuneration for corporate finance services from the Issuer in the next six months.	No
11	Analyst has short position	The investment analyst or another person involved in the preparation of this Report has a short position in the securities or derivatives of the Issuer.	No
12	Analyst has long position	The investment analyst or another person involved in the preparation of this Report has a long position in the securities or derivatives of the Issuer.	No
13	Bryan Garnier executive is an officer	A partner, director, officer, employee or agent of the Bryan Garnier Group, or a member of such person's household, is a partner, director, officer or an employee of, or adviser to, the Issuer or one of its parents or subsidiaries. The name of such person or persons is disclosed above.	No
14	Analyst disclosure	The analyst hereby certifies that neither the views expressed in the research, nor the timing of the publication of the research has been influenced by any knowledge of clients positions and that the views expressed in the report accurately reflect his/her personal views about the investment and issuer to which the report relates and that no part of his/her remuneration was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in the report.	Yes
15	Other disclosures	Other specific disclosures: Report sent to Issuer to verify factual accuracy (with the recommendation/rating, price target/spread and summary of conclusions removed).	No

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at [www.bryangarnier.com](http://www.bryangarnier.com)

<b>London</b>	<b>Paris</b>	<b>New York</b>	<b>Munich</b>	<b>New Delhi</b>
Beaufort House	26 Avenue des Champs Elysées	750 Lexington Avenue	Widenmayerstrasse 29	The Imperial Hotel Janpath
15 St. Botolph Street	75008 Paris	New York, NY 10022	80538 Munich	New Delhi 110 001
London EC3A 7BB	Tel: +33 (0) 1 56 68 75 00	Tel: +1 (0) 212 337 7000	Germany	Tel +91 11 4132 6062
Tel: +44 (0) 207 332 2500	Fax: +33 (0) 1 56 68 75 01	Fax: +1 (0) 212 337 7002	+49 89 2422 62 11	+91 98 1111 5119
Fax: +44 (0) 207 332 2559	Regulated by the	FINRA and SIPC member		Fax +91 11 2621 9062
Authorised and regulated by the	Financial Conduct Authority (FCA) and the			<b>Geneva</b>
Financial Conduct Authority (FCA)	Autorité de Contrôle prudentiel et de			rue de Grenus 7
	resolution (ACPR)			CP 2113
				Genève 1, CH 1211
				Tel +4122 731 3263
				Fax+4122731 3243
				Regulated by the FINMA

#### **Important information**

This document is classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

This report is prepared by Bryan Garnier & Co Limited, registered in England Number 03034095 and its MIFID branch registered in France Number 452 605 512. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange. Registered address: Beaufort House 15 St. Botolph Street, London EC3A 7BB, United Kingdom

This Report is provided for information purposes only and does not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. This Report is for general circulation to clients of the Firm and as such is not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

The information and opinions contained in this Report have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in this Report are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of this Report. Information may be available to the Firm and/or associated companies which are not reflected in this Report. The Firm or an associated company may have a consulting relationship with a company which is the subject of this Report.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firm's prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited immediately and should not rely on it for any purposes whatsoever.

Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC, 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co Limited believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co Limited and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available.